^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Excerpt:
Monotherapy with P demonstrated evidence of anti-tumor activity in heavily pre-treated NSCLC pts with CDKN2A loss or mutation.
DOI:
10.1200/JCO.2019.37.15_suppl.9041
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Excerpt:
In 47 melanoma cell lines homozygous loss, methylation or mutation of CDKN2A gene or loss of protein (p16(INK) (4A) ) predicted sensitivity to the CDK4/6 inhibitor PD0332991, while RB1 loss predicted resistance.
DOI:
10.1111/pcmr.12228